Co dla lekarza POZ oznacza badanie EMPA-REG OUTCOME? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2020
Słowa kluczowe:
cukrzyca, ryzyko sercowo-naczyniowe, empagliflozyna
##plugins.themes.bootstrap3.article.main##
Abstrakt
W pracy przybliżamy wnioski płynące z 3-letniego badania EMPA-REG OUTCOME, w którym chorym na cukrzycę typu 2 z wysokim ryzykiem sercowo-naczyniowym do terapii dołączano empagliflozynę.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Sapilak , B. J., Mastalerz-Migas, A., & Dzida , G. (2020). Co dla lekarza POZ oznacza badanie EMPA-REG OUTCOME?. Medycyna Faktów , 13(4(49), 395-398. https://doi.org/10.24292/01.MF.0420.2
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Sarwar N, Gao P, Seshasai SR et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborativevmeta-analysis of 102 prospective studies. Lancet. 2010; 375: 2215-22.
2. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-59.
3. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-72.
4. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-39.
5. Inzucchi SE, Zinman B, Wanner C et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015; 12: 90-100.
6. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117-28. http://doi.org/10.1056/NEJMoa1504720.
7. Fitchett D, Zinman B, Wanner C et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016; 37(19): 1526-34.
8. Perreault L. EMPA-REG OUTCOME: the endocrinologist’spoint of view. Am J Med. 2017; 130(6S): S51-S6. http://doi.org/10.1016/j.amjmed.2017.04.005.
9. Bays H. Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus. Diabetes Ther. 2013; 4: 195-220.
10. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013; 2: 140-51.
11. Hasan FM, Alsahli M, Gerich J.E. SGLT2 inhibitors in the treatment of type 2 diabetes. Diab Res Clin Pract. 2014; 104: 297-322.
2. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-59.
3. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-72.
4. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-39.
5. Inzucchi SE, Zinman B, Wanner C et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015; 12: 90-100.
6. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117-28. http://doi.org/10.1056/NEJMoa1504720.
7. Fitchett D, Zinman B, Wanner C et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016; 37(19): 1526-34.
8. Perreault L. EMPA-REG OUTCOME: the endocrinologist’spoint of view. Am J Med. 2017; 130(6S): S51-S6. http://doi.org/10.1016/j.amjmed.2017.04.005.
9. Bays H. Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus. Diabetes Ther. 2013; 4: 195-220.
10. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013; 2: 140-51.
11. Hasan FM, Alsahli M, Gerich J.E. SGLT2 inhibitors in the treatment of type 2 diabetes. Diab Res Clin Pract. 2014; 104: 297-322.